Peter Boros

Genetic Immunity LLC develops nanomedicines for immune amplification. It offers an immunetherapy platform technology that includes a plasmid DNA based antigen, a nanomedicine formulation, and a topical administration device that targets antigens to dendritic cells. The company was founded by Julianna Lisziewicz and is headquartered in McLean, VA.

Treos Bio Ltd. engages in the development of a digital cancer vaccine technology platform that provides tailored precision vaccines to patients. It focuses on cancer immunotherapies. The company was founded by john Kenneth Hautman and Julianna Lisziewicz in 2013 and is headquartered in London, the United Kingdom.

eMMUNITY, Inc. operates as a diagnostic and immunotherapy development company. It targets cancer therapy and prevention for genetically related cancer patients. The company was founded by Julianna Lisziewicz in 2013 and si headquartered in Bethesda, MD.

National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD.

Part of Power of The Dream Ventures, Inc., Vidatech Kft is a Hungarian development stage company focused on acquisition and development of intellectual property and technologies. The company was founded by Viktor Rozsnyay.

Part of Bacardi Ltd., Bacardi-Martini Hungary Kft is a company based in Budapest, Hungary.

Virostatics Srl is a privately held small pharmaceutical company based in Sassari, Italy. The Italian company is dedicated to discovering and developing novel compounds for the treatment of cancers and viral diseases. The company focuses on novel, selective, host cell kinase targeted inhibitors and inherently hindering the oncogene myc. The team and advisors combine scientific, business, legal, and technology expertise, spanning from translational science through preclinical and clinical drug development. Virostatics has developed a bioaerosol system to test nebulized drug treatments, inhalers, disinfectants, or devices for virucidal activity in a state-of-the-art biosafety level 3 facility. The company has developed a robust pipeline of proprietary compounds to distinguish themselves from the competition through their unique kinase selectivity, efficacy, and safety profiles. The company was founded by Franco Lori, who has been the CEO since incorporation.